Drug Profile
Eszopiclone - Sumitomo Pharma America
Alternative Names: Esopiclone; Estorra; Lunesta; Lunivia; S-Zopiclone; SEP-0227018; SEP-190; SEP-225441Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Developer Eisai Co Ltd; Sepracor; Sumitomo Pharma America
- Class 2 ring heterocyclic compounds; Esters; Hypnosedatives; Piperazines; Pyrazines; Pyridines; Pyrroles; Sleep disorder therapies; Small molecules
- Mechanism of Action GABA A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Insomnia
- No development reported Generalised anxiety disorder; Major depressive disorder
Most Recent Events
- 30 Apr 2019 The FDA recommends to update the label of eszopiclone (Lunesta®) for Insomnia to include Black Box warning regarding the complex sleep behaviors
- 31 May 2018 Eisai completes a phase II trial for Insomnia in Japan (PO) (UMIN000024462)
- 01 Oct 2016 Eisai initiates enrolment in a phase II trial for Insomnia in Japan (PO) (UMIN000024462)